Investigating the loss of LKB1 expression may have significant “theranostic” implications in the management of patients with operable NSCLC, and the investigation of LKB1 loss could be a step forward in the procedure of precision medicine in lung cancer. Here, STK11 is linked to non-small cell lung carcinoma.